
BioCardia Inc. (BCDA) Stock Forecast & Price Target
BioCardia Inc. (BCDA) Analyst Ratings
Bulls say
BioCardia Inc. is advancing its CardiAMP autologous mononuclear cell therapy platform, which has demonstrated significant reductions in heart death equivalents and major adverse cardiovascular and cerebrovascular events (MACCE) in high-risk patients through a Phase 3 clinical trial. The company’s therapies are associated with improved quality of life and decreased mortality rates when used alongside existing heart failure medications, indicating strong potential for long-term benefits in managing ischemic heart failure and refractory angina. Additionally, the ongoing enrollment for CardiALLO, the allogeneic mesenchymal stem cell therapy, further supports BioCardia's growth potential in addressing unmet medical needs in the cardiovascular and pulmonary disease sectors.
Bears say
BioCardia Inc is facing significant challenges, as its CardiAMP HF therapy failed to meet critical clinical endpoints, which raises concerns about the viability of the treatment. The lack of projections for the CardiALLO program further complicates the company’s ability to secure adequate funding, crucial for progressing its therapeutic developments. Additionally, the potential for dilutive capital raises exacerbates the financial uncertainty surrounding the company’s future performance.
This aggregate rating is based on analysts' research of BioCardia Inc. and is not a guaranteed prediction by Public.com or investment advice.
BioCardia Inc. (BCDA) Analyst Forecast & Price Prediction
Start investing in BioCardia Inc. (BCDA)
Order type
Buy in
Order amount
Est. shares
0 shares